TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.
Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), George Seed(Institute of Cancer Research), Ursula McGovern(University College Hospital), Robert J. Jones(Beatson West of Scotland Cancer Centre), Emma Hall(Institute of Cancer Research), Susana Miranda(Royal Marsden NHS Foundation Trust), Omi Parikh(Royal Blackburn Teaching Hospital), Christy Ralph(University of Leeds), Peter Chatfield(Institute of Cancer Research), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Núria Porta, Tony Elliott(The Christie Hospital), Aude Espinasse(Institute of Cancer Research), Simon J. Crabb(University of Southampton), Isabel Syndikus(San Antonio College), Suzanne Carreira(Institute of Cancer Research), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Mohini Varughese(Musgrove Park Hospital), Cláudia Bertan(Institute of Cancer Research), Suneil Jain(Queen's University Belfast)
Cited by 45
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k